egfrviii car t cells
Cell therapyexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02844062)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Epidermal growth factor receptor erbB1Immunity, passive
EGFR immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-egfrviii car t cells
- egfrviii car t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07244666 | Early Phase 1 (Phase 1) | Nov 15, 2025 | Leman Biotech Co., Ltd, Zhejiang University |
| NCT03283631 | Phase 1 | May 30, 2018 | Duke University, National Cancer Institute (NCI) |
| NCT02664363 | Phase 1 | Feb 1, 2017 | Duke University |
| NCT02844062 | Phase 1 | Jul 1, 2016 | Capital Medical University, Marino Biotechnology Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Leman Biotech Co., Ltd | For profit | 1 | 0 | 1 | 2025 |
| Marino Biotechnology Co., Ltd. | For profit | 1 | 0 | 1 | 2016 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2018 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2025 |
6 organizations
Page 1 / 1